Biogen Inc (BIIB)

[XenaLives]

BIIB - 3 day chart

Entering an area of low long term resistance, other indicators looking bullish. It could get interesting here...

[craigferg501]

Biogen Inc. raises forecast on beating second quarter revenue estimates. TECFIDERA, Biosimilars shine.Earnings Infographic

[blue finch]

Who knows jimmy
But we certainly will find out eventually

Good luck

[jimmy667]

Market Yawns at BIIBs unimpressive 54 week ALZ drug results.

[jimmy667]

Biogen's 1st Poster from AAIC is up on website.

Go to Biogen website>Investor Relations>Presentations.

They have another one tomorrow regarding early detection of ALZ, understandable since the current study is Prodromal and Mild cases of ALZ.

See how the market reacts to both Biogen and Anavex on Monday.

If the market likes this presentation then Technically BIIB has mapped out an almost perfect cup and handle formation (late April to NOW) already and all would be sitting right at the break-out trigger point. This could be a HUGE gainer over the next few days IF the Market likes this Presentation at AAIC. However, just as likely to see a drop on the good ole Biotech "Sell the News' reaction.

[blue finch]

I'm shocked about a non announcement for the buyout of anavex at this time

[Cbdpotential]

Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs

Source: Business Wire
Industry leader brings deep experience in communications, patient advocacy and government policy

Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.

Ms. Steele, who brings more than 25 years of public affairs experience to Biogen, will lead the company’s corporate, product, and internal communications as well government affairs and patient advocacy efforts.

“Catherine is joining us at an exciting time in the evolution of Biogen,” said Chief Executive Officer Michel Vounatsos. “As we strengthen our pipeline, reaffirm our commitment to neuroscience and look to enter new therapeutic areas and markets globally, Catherine will play a crucial role in helping align our business with key public and patient audiences and establish Biogen with new stakeholders globally.”

Ms. Steele most recently served as Global Head, Communications and Patient Relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies. She also led the company’s social media and patient relations activities. Her career in the biopharma industry began at Roche, where she spent more than a decade in global communications and policy leadership roles.

"I am privileged to join Biogen, a respected and recognized pioneer in neuroscience," said Ms. Steele. "I look forward to building upon that legacy and being part of this company whose commitment to patients, families and society affected by neurological diseases is unwavering."

Ms. Steele holds dual undergraduate degrees in French and political science from the University of New Brunswick and a Master of Arts degree in political science from Carleton University.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.



View source version on businesswire.com: http://www.businesswire.com/news/home/20170628005103/en/

Biogen
MEDIA CONTACT:
Matt Fearer, [phone]
[e-mail]
or
INVESTOR CONTACT:
Matt Calistri, [phone]
[e-mail]

[blue finch]

If they are buying anavex for 40 million
It's the best kept secret ever on Wall Street

[blue finch]

It's nice to dream


Maybe waiting another few years is a better idea for a return on my money

[XenaLives]

I predict Anavex CEO Missling would tell them to go fly a kite if that was the offer. Maybe upfront payment and licensing for MS - nothing more.

[blue finch]

I predict biogen announces that it is buying anavex life sciences for 40 billion dollars Tuesday

[Cbdpotential]

Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017

Source: Business Wire
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.



View source version on businesswire.com: http://www.businesswire.com/news/home/20170620005997/en/

Biogen
Karen Jewell, 781-464-2442
Investor Relations

[Cbdpotential]

Biogen Announces Management Change

Source: Business Wire
Biogen (NASDAQ: BIIB) announced today that Paul Clancy, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to join another biopharmaceutical company. Mr. Clancy will remain at the Company through the second quarter and assist with the transition.

“I want to thank Paul for his more than sixteen years of distinguished service to Biogen, and especially for his last ten years as our CFO,” stated Michel Vounatsos, Biogen’s Chief Executive Officer. “Paul helped transform Biogen into the global biotechnology leader it is today and helped to prepare us for the bright future we believe lies ahead.”

Paul Clancy commented, “I am fortunate to have worked in such a remarkable organization and am pleased to have been a part of Biogen’s success. Biogen has a rich portfolio of products and pipeline and can look forward to even greater success under Michel’s leadership.”

The Company also announced that Greg Covino, Biogen’s Chief Accounting Officer, will serve as the Company’s interim Principal Financial Officer as the company conducts a search for a new CFO.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen’s business activities. These forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; potential future healthcare reforms; the occurrence of adverse safety events; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.



View source version on businesswire.com: http://www.businesswire.com/news/home/20170613006328/en/

Biogen
MEDIA CONTACT:
Jason Glashow, [phone]
[e-mail]
or
INVESTOR CONTACT:
Matt Calistri, [phone]
[e-mail]

[XenaLives]

An article on Biogen's failed MS drug.

Biogen Loses Big MS Gamble As Anti-LINGO Fails Clinical Trial

Biogen is back to the drawing board with its potentially revolutionary MS drug candidate. (iStockphoto)
AMY REEVES6/07/2016
FacebookLinkedInPrintTwitterShare Reprints
Biogen (BIIB) said Tuesday that its risky but potentially transformative multiple-sclerosis drug candidate had failed its clinical trial, driving the big biotech's stock down sharply on Tuesday.

Biogen said that its drug opicinumab, better known by its medical acronym anti-LINGO, hadn't met either the primary or secondary endpoints in its mid-stage trial, which measured improvements in physical and cognitive functions as well as disability and disease progression. Biogen nonetheless said that "evidence of a clinical effect with a complex, unexpected dose-response was observed," so it was analyzing the results in hopes of designing another study.

Anti-LINGO is a novel technology that promised to be the first to rebuild myelin -- the fatty layer around the nerve cells that erodes in MS patients -- and thereby actually reverse the progression of the disease. Results last year of an earlier trial of optic neuritis -- a form of vision loss in MS patients associated with demyelination -- were technically positive but ambiguous enough that expectations were low going into the MS results.

"This was one of the most unknown, unpredictable major clinical events investors were trying to do work on," wrote RBC Capital Markets analyst Michael Yee in a research note. "It also reflects the challenging dynamic with the stock for many growth investors in that it is seen as a 'high risk, high reward' pipeline company, and it's hard to get conviction on the events without data despite lots of potential upside if it works."

Biogen's other high-risk, high-reward program is in Alzheimer's disease, which was very promising in earlier trials but is in a disease area with a long history of failure. The next batch of data on that isn't expected for more than a year, though an expected Eli Lilly (LLY) report on its own Alzheimer's drug late this year could provide some read-across, analysts say.

Biogen shares tumbled 12.8% to 252.86 on the stock market today. The stock gapped below its 200-day and 50-day moving averages.

AMY REEVES | Facebook | @IBD_Areeves

http://www.investors.com/news/technology/biogen-loses-big-ms-gamble-as-anti-lingo-fails-clinical-trial/

[wadirum1]

Yes, BIIB very clearly rolling over:

[XenaLives]

3 day chart - not looking good.

Stock is trading under major VBP resistance and 50 sma has crossed under 200 (represented by 17 and 67 on this chart).

New CEO has got to get some excitement going.

[wadirum1]

Well, I made a few percent on this. And now I have sold. Beats money market!

[wadirum1]

I agree. Seems like a fairly high-probability scalp to buy in this range and ride it up to at least $290.

[Cbdpotential]

I have a feeling this is above 300 again by EOY
Jmho

[wadirum1]

Maybe I jumped back in too soon. Started buying at 252 and added more yesterday. I guess I would add even more if we see 230s.

Sure would be nice to see a 4M share day with a close up above 255...

[Cbdpotential]

230's

[Cbdpotential]

I bet we see a nice buying opportunity here
Been waiting for this level
I'm likely adding soon

[blue finch]

What's really funny is your lol
Post deleted


That's hysterical
Sorry


Albatross

[blue finch]

Wow
Biogen loves the Tau technology

Read yesterday conference call transcript

[blue finch]

Not enough information going forward

[Cbdpotential]

So far so good!

[ExtremelyBullishZig]

I wouldn't worry either way. The stock doesn't move due to Tom or Xena...unles the are representing institutions and buying/selling a ton.

[ExtremelyBullishZig]

No...what happened?

[blue finch]

Did you happen to see the post about Tom P1
Yesterday
It came from Boston sports nut

[Cbdpotential]

Need to see this over 300 again
Patience $biib

[Cbdpotential]

Investors want Biogen to buy something to bolster revenues in the face of MS competition and patent challenges, as well as a lack of near-term catalysts. The company’s new chief executive officer, Michel Vounatsos, recently spoke at the Cowen & Company Annual Health Care Conference and suggested that, according to The Motley Fool, “more activity has gone on behind the scenes than meets the eye. He said that Biogen does want to bolster its pipeline with additional early-stage assets.”

[Cbdpotential]

Good day
$BIIB

[jfkspire]

OK I get it now as regards the Partnership,, Thanx!!

[XenaLives]

A good article on antisense which Biogen is partnering with Ionis for CNS.

http://www.alsa.org/news/vision-express/articles/april2016/the-neuro-collaborative.html?utm_source=natlnewsletter&utm_medium=email&utm_campaign=april2016

[Cbdpotential]

270's holding strong imo

[Cbdpotential]

Looking good $biib

[blue finch]

We will probably get approval for Alzheimer's in Australia first

[ExtremelyBullishZig]

I do not know how to answer that. If we have approval for alzheimers, then yes.

[blue finch]

Do you think we will see 100 dollars per share in the next 18 months

[DewDiligence]

Will this put cash in Biogen's pocket?

No—BIVV shares will be distributed free to BIIB shareholders.

[XenaLives]

Wondering if the Biogen spin off of Bioverativ is putting the announcement of Anavex partnership or possible buy out on hold.

If it's a buyout with an exchange of stock it would go over better with stockholders after rolling out Bioverativ as a shareholder dividend.

Also will Biogen be selling their share (did I read 25%?) for cash, and how much could it raise?

How might this affect an Anavex/Biogen transaction.

[XenaLives]

Helpful info on Bioverativ competition:

Biogen’s haemophilia spin-out Bioverativ to launch early 2017
Andrew McConaghie Andrew McConaghie
August 9, 2016

Biogen says the spin out of its haemophilia division will take place in early 2017, with the new standalone firm to be called Bioverativ.

The Boston, Massachusetts company is a significant player in the haemophilia market, and the creation of Bioverativ as a standalone will open up opportunities for growth it and for Biogen.

The company has been under pressure to find new ways of reinvigorating its revenues as its biggest earner, multiple sclerosis drug Tecfidra, has seen its earnings slow down.

Biogen has two already-marketed products, Eloctate (antihaemophilic factor (recombinant)) and Alprolix (coagulation factor IX (recombinant)) earned combined revenues of $640 million in the year ended 31 March.

The chief executive of the company will be John Cox, currently executive vice president of pharmaceutical operations and technology at Biogen.

“As an independent and focused company, we believe that Bioverativ will be uniquely positioned to drive progress and advance the standard of care for people living with haemophilia,” said John Cox. “Working closely with the haemophilia community, we hope to transform lives by accelerating innovation for people and caregivers living with haemophilia.”

Bioverativ will continue to market Eloctate and Alprolix for the treatment of haemophilia A and B, respectively, under Biogen’s existing collaboration with Swedish Orphan Biovitrum (Sobi). Bioverativ says it expects to continue developing the two drugs, including conducting studies to explore the potential benefits of Fc fusion technology on long-term joint health, immunogenicity and immune tolerance induction in haemophilia patients who develop inhibitors.

The haemophilia market is heading for major change in the next year or two, with a number of potentially groundbreaking drugs in late stage development.

Roche’s emicizumab is a bispecific antibody drug in phase 3 trials which currently looks set for approval by 2018.

Even more exciting is the promise of gene therapy and an RNAi therapy which could bring patients closer to a cure for the condition.

BioMarin’s has just provided proof-of-concept data for its BMN270, with a phase 1 /2 trial showing the gene therapy restored the vital Factor VIII clotting factor in haemophilia A patients.

Meanwhile Alnylam’s RNAi therapy fitusiran is a once-monthly injection in phase 1 development. The company recently unveiled data which showed the drug had eliminated all bleeding events in the 17 patients in the trial.

Against this background, Bioverativ will advance its own pipeline across a range of approaches. These include longer-acting factor therapies using its XTEN technology platform, and a non-factor bi-specific antibody programme to treat patients with haemophilia A and patients with inhibitors. The company is also working on gene therapy for haemophilia A and B, as well as ongoing research relating to sickle cell disease.

http://pharmaphorum.com/news/biogens-haemophilia-spin-bioverativ-launch-early-2017/

[XenaLives]

A little confusing here -

Is this just Biogen tying up loose ends for the Bioverativ launch?

Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology

MOUNTAIN VIEW, CA--(Marketwired - January 05, 2017) - Amunix Operating Inc. announced today that Biogen (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to develop and commercialize a novel, recombinant Factor IX product candidate that incorporates Amunix' XTEN technology to provide extended half-life. The agreement is part of Biogen's hemophilia business, which is expected to launch as Bioverativ on February 1, 2017 as an independent, public company focused on the discovery, research, development and commercialization of treatments for hemophilia and other rare blood disorders.

Under the terms of the agreement, Amunix will receive an upfront $1.25 million payment and will also be eligible to receive up to $17.25 million in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales from Factor IX products incorporating Amunix' proprietary XTEN technology.

In March 2011, Amunix and Biogen initiated a Research and Option Agreement under which both companies would collaborate to combine Amunix' expertise in protein half-life extension and its proprietary XTEN technology with Biogen's expertise in both hemophilia and engineering long-lasting coagulation factors. Biogen, or its planned spin-out company Bioverativ, will be responsible for developing, manufacturing and commercializing therapeutic product candidates resulting from the collaboration.

"The ongoing research collaboration with Biogen has resulted in the discovery of molecules that retain procoagulant activity while exhibiting significantly improved half-life in animal models," said Volker Schellenberger, PhD, Amunix President and Chief Executive Officer. "Fruitful collaborations such as the one with Biogen, which will now continue with Bioverativ, are a central element of Amunix' strategy to facilitate the use of XTEN in a wide range of therapeutic applications."

About Amunix:

Amunix, based in Mountain View, CA, is a privately held biotechnology company focused on the discovery and development of biologics with improved in vivo half-lives. Amunix' half-life extension technology is based on XTEN -- hydrophilic, unstructured, biodegradable proteins that impart a number of favorable properties upon the molecules to which they are attached. XTEN can be recombinantly fused or chemically conjugated to peptides, proteins, and other pharmaceuticals. In addition to the advantages of reduced dosing frequency, XTENylation also stabilizes plasma drug concentrations, which often results in increased efficacy as well as reduced side effects. Two genetically fused XTENylated products have been tested clinically. VRS-859 (exenatide-XTEN) has been tested through Phase I in the treatment of diabetes and VRS-317 (human growth hormone-XTEN) is currently in Phase III testing. Amunix is also working with additional partners, including Eli Lilly, Bioverativ, Roche, Janssen, Naia and other undisclosed companies in a wide range of therapeutic areas.

Amunix is developing an internal pipeline of ProTIA (Protease Triggered Immune Activator) immuno-oncology therapeutics. ProTIAs are bispecific molecules that bind tumor antigens and T cells. ProTIAs are administered as long-acting prodrugs that can be activated in the tumor environment by tumor-associated proteases. Amunix is actively seeking partnerships for applications of its XTEN technology and its ProTIA platform. For additional information about the company, please visit www.amunix.com.

Contact:
Volker Schellenberger, Ph.D.
President and CEO
Tel: [phone]
[e-mail]

[XenaLives]

Good summary of recent Biogen developments - but not advocating the site in general:

ecember 28, 2016: Biogen, Inc. spokesperson says to set Spinraza wholesale acquisition cost (WAC) annual price at $375K after loading doses. Sees wholesale acquisition cost at $750K first 12 months, with price at $125K per vial. On 12/23/16, the FDA approved the first drug for spinal muscular atrophy; Spinraza is marketed by Biogen.

December 20, 2016: Biogen announced that its board of directors has approved the planned spin-off of its hemophilia business, which will be known as Bioverativ Inc., and declared a special dividend distribution of all of the outstanding shares of Bioverativ common stock.

For every two shares of Biogen common stock held of record as of the close of business on January 17, 2017, Biogen shareholders will receive one share of Bioverativ common stock. Registered shareholders will receive cash in lieu of fractional shares. The special dividend distribution is expected to be paid on February 1, 2017.

The distribution of Bioverativ common stock will complete the proposed separation of the hemophilia business from Biogen. After the separation, Bioverativ will become an independent, publicly-traded company focused on hemophilia and other rare blood disorders, and Biogen will retain no ownership interest. Bioverativ has applied for listing of its common stock on the NASDAQ Global Select Market under the ticker symbol BIVV.

The spin-off has been structured to qualify as a tax-free distribution to U.S. holders of Biogen’s common stock for U.S. federal income tax purposes. However, cash received in lieu of fractional shares may be taxable to such shareholders. Shareholders should consult their tax advisors with respect to U.S. federal, state, local and non-U.S. tax consequences of the separation and distribution of Bioverativ. No action is required by Biogen shareholders to receive shares of Bioverativ common stock as part of this special dividend distribution. Any holder of Biogen common stock who sells shares of Biogen common stock on or before the distribution date may be selling the entitlement to receive shares of Bioverativ common stock.

Following the spin-off, Bioverativ will be a global biotechnology company dedicated to advancing the research, development and commercialization of innovative therapies to address areas of serious unmet need for people with hemophilia and other rare blood disorders.

http://www.guerillastocktrading.com/stocks/biogen/

[XenaLives]

Will this put cash in Biogen's pocket? How much?

Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017
Print
Alert
Biogen Inc. (NASDAQ:BIIB)
Historical Stock Chart

1 Month : From Dec 2016 to Jan 2017
Click Here for more Biogen Inc. Charts.

Biogen Inc. (NASDAQ: BIIB) announced today that Bioverativ, the planned spin-off of Biogen’s hemophilia business, will host an Investor Day on January 6, 2017. The webcast will be live on Friday, January 6, 2017 at 10:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.

The planned spin-off of Bioverativ is expected to be completed on February 1, 2017.

Following the spin-off, Bioverativ will be an independent, publicly-held global biotechnology company dedicated to advancing the research, development and commercialization of innovative therapies to address areas of serious unmet need for people with hemophilia and other rare blood disorders.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005043/en/

Biogen
Karen Jewell, 781-464-2442
Investor Relations

[Cbdpotential]

Looking good
$biib

[CashMoney75]

AVXL. NOW!!

[Cbdpotential]

Yep yep I know all about it

[ExtremelyBullishZig]

They just don't get it over there. The combo patent would extend the patent protection of the molecule used in the combo in the AD designation. Therefore you can sell the monotherapy knowing that the "unused" combo patent covers the molecule for AD sold by itself or not. Companies have many tricks to extend patents.

Have you read the Anavex initiated interview summary on the USPTO public PAIR database from 12-19 about the combo patent?

[Cbdpotential]

This is why I buy at multiple levels on the down tick ... Doesn't always go as far down as it "should"

Looking good now imo
Back up

Do I smell more news?